Site-Specific Treatment and Remission Patterns in Multisite Mucous Membrane Pemphigoid.
5 affiliations
- 1University of Texas Southwestern Medical Center, Dallas.
- 2Peter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas.
- 3Department of Dermatology, University of Texas Southwestern Medical Center, Dallas.
- 4Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas.
- 5Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
Abstract
Importance
Mucous membrane pemphigoid (MMP) is a chronic autoimmune blistering disease associated with progressive mucosal scarring and substantial morbidity. Prior studies have often reported remission rates in cohorts combining localized and multisite disease, with limited data on simultaneous remission across all involved sites in patients with multisite disease.Objective
To evaluate multisite complete remission (mCR) and site-specific treatment response patterns in patients with multisite MMP.Design, setting, and participants
This retrospective cohort study took place at a single tertiary dermatology and ophthalmology referral center at the University of Texas Southwestern Medical Center between January 1, 2013, and January 1, 2025. Patients with MMP confirmed by immunopathology, disease involving 2 or more anatomic sites, and 12 months posttreatment follow-up were included.Main outcomes and measures
The primary outcome was mCR, defined as concurrent complete remission across all involved sites regardless of therapy. Secondary outcomes included site-specific remission and relapse patterns, time to remission, and treatment-associated adverse events.Results
Among 77 patients (55 [71%] female; median [IQR] age at diagnosis, 66 [59-72] years), 68 (88%) had high-risk disease involving ocular, laryngeal, esophageal, or anogenital sites. Oral disease was most common, present in 73 patients (95%), followed by ocular disease in 51 (66%) and nasal disease in 38 (49%). Thirty-five patients (45%) achieved mCR in a median (IQR) of 32.0 (20.7-55.3) months. Although all patients demonstrated improvement and 64 (83%) achieved CR at 1 or more sites, persistent oral and ocular diseases frequently prevented mCR. Relapses following site-level CR occurred in 28 of the 64 patients (44%), most frequently at the oral (18 of 28 patients [64%]) and ocular mucosa (14 of 28 patients [50%]); some patients experienced relapse at multiple sites. Rituximab-based regimens and Janus kinase inhibitor therapy were associated with high rates of improvement. Serious adverse events occurred most frequently with cyclophosphamide monotherapy and Janus kinase inhibitor therapy.Conclusions and relevance
In this cohort study, fewer than half of patients with multisite MMP achieved simultaneous multisite remission despite high rates of site-level response. Persistent oral and ocular diseases disproportionately limited global disease control, supporting a site-specific model of disease behavior and highlighting the need for standardized multisite remission outcomes in future studies.
Related
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature
- Circadian syndrome and incident multisite pain among middle-aged and older Chinese adults: component-specific and longitudinal analyses from CHARLS
- Site-Specific Trends in Tumor Distribution, Treatment Patterns, and Survival in Head and Neck Cancer: A SEER Database Analysis.
- Describing Patient Characteristics, Treatment Patterns, and Disease Burden Among Patients with Alopecia Areata in Mexico: A Secondary Analysis of the Adelphi Real World Alopecia Areata Disease Specific Programme
- Remission of Type 2 Diabetes in Linked Health Records: Uncommon, Short-Lived, and More Often Ended by Treatment Restart Than by Rising HbA1c
BibTeX
@article{mcaleer2026sitespecific,
title = {{Site-Specific Treatment and Remission Patterns in Multisite Mucous Membrane Pemphigoid.}},
author = {Leah McAleer and Tatum La and Mingyue Li and Jennifer H Cao and Arturo R Dominguez},
journal = {JAMA dermatology},
year = {2026},
month = oct,
doi = {10.1001/jamadermatol.2026.4256},
url = {https://europepmc.org/article/MED/42949703},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Site-Specific Treatment and Remission Patterns in Multisite Mucous Membrane Pemphigoid.
AU - Leah McAleer
AU - Tatum La
AU - Mingyue Li
AU - Jennifer H Cao
AU - Arturo R Dominguez
PY - 2026
DA - 2026/10/28
JO - JAMA dermatology
DO - 10.1001/jamadermatol.2026.4256
UR - https://europepmc.org/article/MED/42949703
AB - Importance Mucous membrane pemphigoid (MMP) is a chronic autoimmune blistering disease associated with progressive mucosal scarring and substantial morbidity. Prior studies have often reported remission rates in cohorts combining localized and multisite disease, with limited data on simultaneous remission across all involved sites in patients with multisite disease.Objective To evaluate multisite complete remission (mCR) and site-specific treatment response patterns in patients with multisite MMP.Design, setting, and participants This retrospective cohort study took place at a single tertiary dermatology and ophthalmology referral center at the University of Texas Southwestern Medical Center between January 1, 2013, and January 1, 2025. Patients with MMP confirmed by immunopathology, disease involving 2 or more anatomic sites, and 12 months posttreatment follow-up were included.Main outcomes and measures The primary outcome was mCR, defined as concurrent complete remission across all involved sites regardless of therapy. Secondary outcomes included site-specific remission and relapse patterns, time to remission, and treatment-associated adverse events.Results Among 77 patients (55 [71%] female; median [IQR] age at diagnosis, 66 [59-72] years), 68 (88%) had high-risk disease involving ocular, laryngeal, esophageal, or anogenital sites. Oral disease was most common, present in 73 patients (95%), followed by ocular disease in 51 (66%) and nasal disease in 38 (49%). Thirty-five patients (45%) achieved mCR in a median (IQR) of 32.0 (20.7-55.3) months. Although all patients demonstrated improvement and 64 (83%) achieved CR at 1 or more sites, persistent oral and ocular diseases frequently prevented mCR. Relapses following site-level CR occurred in 28 of the 64 patients (44%), most frequently at the oral (18 of 28 patients [64%]) and ocular mucosa (14 of 28 patients [50%]); some patients experienced relapse at multiple sites. Rituximab-based regimens and Janus kinase inhibitor therapy were associated with high rates of improvement. Serious adverse events occurred most frequently with cyclophosphamide monotherapy and Janus kinase inhibitor therapy.Conclusions and relevance In this cohort study, fewer than half of patients with multisite MMP achieved simultaneous multisite remission despite high rates of site-level response. Persistent oral and ocular diseases disproportionately limited global disease control, supporting a site-specific model of disease behavior and highlighting the need for standardized multisite remission outcomes in future studies.
SN - 2168-6068
SN - 2168-6084
ER -